Full Press Release Details
PellePharm Announces Topline Results From Phase 2 Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing.
BBIO
PellePharm Announces Topline Results From Phase 2 Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing
Key Takeaway: PellePharm Announces Topline Results From Phase 2 Study Of Topical Patidegib In Gorlin Syndrome Basal Cell Carcinomas And Third Closing Of A $20 Million Series B Financing